Felzartamab Reduces aPLA2R Ab by Selectively Depleting CD38+ Plasma Cells and Plasmablasts, the Main Pathogenic Cellular Drivers of Disease in Primary Membranous Nephropathy (PMN): SA-PO910
Flesher, Donna, Boxhammer, Rainer, Kräft, Tabea, Kivman, Lisa, Haertle, Stefan, Dudani, Jaideep, Gilbert, Houston N., Patel, Uptal D., Rovin, Brad H.
Published in Journal of the American Society of Nephrology (01.11.2023)
Published in Journal of the American Society of Nephrology (01.11.2023)
Get full text
Journal Article
Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
Bass, Michael B, Sherman, Steven I, Schlumberger, Martn J, Davis, Michael T, Kivman, Lisa, Khoo, Huan-Mei, Notari, Kimberly H, Peach, Matthew, Hei, Yong-jiang, Patterson, Scott D
Published in The journal of clinical endocrinology and metabolism (01.11.2010)
Published in The journal of clinical endocrinology and metabolism (01.11.2010)
Get full text
Journal Article